Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients

Carlo Dufour, Johanna Svahn, Andrea Bacigalupo, Daniela Longoni, Stefania Varotto, Anna Paola Iori, Francesca Bagnasco, Anna Locasciulli, Giuseppe Menna, Ugo Ramenghi, Marina Lanciotti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Objectives. Various drugs and xenobiotics are involved in the pathogenesis of acquired aplastic anemia. Their harmful potential depends on the amount of exposure to them and on the detoxifying capacity of the recipient. Genetic polymorphisms of some important detoxifying enzymes are associated with low or absent cata-lytic activity of the protein. We assessed whether, in a Caucasian population, low or null activity polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 were associated with the risk of developing aplastic anemia and with the response to immunosuppressive therapy. Design and Methods. In 77 Caucasian patients with aplastic anemia and in 156 normal controls we evaluated the distribution of the following polymorphisms which are associated with low or no activity of the corresponding enzyme: (i)-290 A→G of the CYP3A4 gene, deletions of (ii) GSTT1 and (iii) GSTM1 genes, (iv) 313A→G of the GSTP1 gene and (v) 609 C→T of the NQO1 gene. Results. The distribution of the genotypes of all tested polymorphisms was not different in patients and controls. No differences were seen among the patients when the group was subdivided by age and severity of the disease. Only the GSTM1 null genotype was significantly more frequent in male patients than in male controls. The frequency of all tested polymorphisms did not differ in patients who did or did not respond to immunosuppressive therapy. Interpretations and Conclusions. The low/null activity polymorphisms of the detoxifying enzymes CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 are not associated with the risk of developing aplastic anemia or to the response to immunosuppressive therapy in Caucasian patients.

Original languageEnglish
Pages (from-to)1027-1031
Number of pages5
JournalHaematologica
Volume90
Issue number8
Publication statusPublished - Aug 2005

Fingerprint

Cytochrome P-450 CYP3A
Genetic Polymorphisms
Aplastic Anemia
Immunosuppressive Agents
Enzymes
Genotype
Genes
Gene Deletion
Xenobiotics
Idiopathic Aplastic anemia
Therapeutics
Pharmaceutical Preparations
Population
Proteins

Keywords

  • Aplastic anemia
  • CYP3A4
  • GSTs
  • NQO1

ASJC Scopus subject areas

  • Hematology

Cite this

Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. / Dufour, Carlo; Svahn, Johanna; Bacigalupo, Andrea; Longoni, Daniela; Varotto, Stefania; Iori, Anna Paola; Bagnasco, Francesca; Locasciulli, Anna; Menna, Giuseppe; Ramenghi, Ugo; Lanciotti, Marina.

In: Haematologica, Vol. 90, No. 8, 08.2005, p. 1027-1031.

Research output: Contribution to journalArticle

Dufour, C, Svahn, J, Bacigalupo, A, Longoni, D, Varotto, S, Iori, AP, Bagnasco, F, Locasciulli, A, Menna, G, Ramenghi, U & Lanciotti, M 2005, 'Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients', Haematologica, vol. 90, no. 8, pp. 1027-1031.
Dufour, Carlo ; Svahn, Johanna ; Bacigalupo, Andrea ; Longoni, Daniela ; Varotto, Stefania ; Iori, Anna Paola ; Bagnasco, Francesca ; Locasciulli, Anna ; Menna, Giuseppe ; Ramenghi, Ugo ; Lanciotti, Marina. / Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. In: Haematologica. 2005 ; Vol. 90, No. 8. pp. 1027-1031.
@article{1ef60999a2a44699b82ddb1df21376f6,
title = "Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients",
abstract = "Background and Objectives. Various drugs and xenobiotics are involved in the pathogenesis of acquired aplastic anemia. Their harmful potential depends on the amount of exposure to them and on the detoxifying capacity of the recipient. Genetic polymorphisms of some important detoxifying enzymes are associated with low or absent cata-lytic activity of the protein. We assessed whether, in a Caucasian population, low or null activity polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 were associated with the risk of developing aplastic anemia and with the response to immunosuppressive therapy. Design and Methods. In 77 Caucasian patients with aplastic anemia and in 156 normal controls we evaluated the distribution of the following polymorphisms which are associated with low or no activity of the corresponding enzyme: (i)-290 A→G of the CYP3A4 gene, deletions of (ii) GSTT1 and (iii) GSTM1 genes, (iv) 313A→G of the GSTP1 gene and (v) 609 C→T of the NQO1 gene. Results. The distribution of the genotypes of all tested polymorphisms was not different in patients and controls. No differences were seen among the patients when the group was subdivided by age and severity of the disease. Only the GSTM1 null genotype was significantly more frequent in male patients than in male controls. The frequency of all tested polymorphisms did not differ in patients who did or did not respond to immunosuppressive therapy. Interpretations and Conclusions. The low/null activity polymorphisms of the detoxifying enzymes CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 are not associated with the risk of developing aplastic anemia or to the response to immunosuppressive therapy in Caucasian patients.",
keywords = "Aplastic anemia, CYP3A4, GSTs, NQO1",
author = "Carlo Dufour and Johanna Svahn and Andrea Bacigalupo and Daniela Longoni and Stefania Varotto and Iori, {Anna Paola} and Francesca Bagnasco and Anna Locasciulli and Giuseppe Menna and Ugo Ramenghi and Marina Lanciotti",
year = "2005",
month = "8",
language = "English",
volume = "90",
pages = "1027--1031",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients

AU - Dufour, Carlo

AU - Svahn, Johanna

AU - Bacigalupo, Andrea

AU - Longoni, Daniela

AU - Varotto, Stefania

AU - Iori, Anna Paola

AU - Bagnasco, Francesca

AU - Locasciulli, Anna

AU - Menna, Giuseppe

AU - Ramenghi, Ugo

AU - Lanciotti, Marina

PY - 2005/8

Y1 - 2005/8

N2 - Background and Objectives. Various drugs and xenobiotics are involved in the pathogenesis of acquired aplastic anemia. Their harmful potential depends on the amount of exposure to them and on the detoxifying capacity of the recipient. Genetic polymorphisms of some important detoxifying enzymes are associated with low or absent cata-lytic activity of the protein. We assessed whether, in a Caucasian population, low or null activity polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 were associated with the risk of developing aplastic anemia and with the response to immunosuppressive therapy. Design and Methods. In 77 Caucasian patients with aplastic anemia and in 156 normal controls we evaluated the distribution of the following polymorphisms which are associated with low or no activity of the corresponding enzyme: (i)-290 A→G of the CYP3A4 gene, deletions of (ii) GSTT1 and (iii) GSTM1 genes, (iv) 313A→G of the GSTP1 gene and (v) 609 C→T of the NQO1 gene. Results. The distribution of the genotypes of all tested polymorphisms was not different in patients and controls. No differences were seen among the patients when the group was subdivided by age and severity of the disease. Only the GSTM1 null genotype was significantly more frequent in male patients than in male controls. The frequency of all tested polymorphisms did not differ in patients who did or did not respond to immunosuppressive therapy. Interpretations and Conclusions. The low/null activity polymorphisms of the detoxifying enzymes CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 are not associated with the risk of developing aplastic anemia or to the response to immunosuppressive therapy in Caucasian patients.

AB - Background and Objectives. Various drugs and xenobiotics are involved in the pathogenesis of acquired aplastic anemia. Their harmful potential depends on the amount of exposure to them and on the detoxifying capacity of the recipient. Genetic polymorphisms of some important detoxifying enzymes are associated with low or absent cata-lytic activity of the protein. We assessed whether, in a Caucasian population, low or null activity polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 were associated with the risk of developing aplastic anemia and with the response to immunosuppressive therapy. Design and Methods. In 77 Caucasian patients with aplastic anemia and in 156 normal controls we evaluated the distribution of the following polymorphisms which are associated with low or no activity of the corresponding enzyme: (i)-290 A→G of the CYP3A4 gene, deletions of (ii) GSTT1 and (iii) GSTM1 genes, (iv) 313A→G of the GSTP1 gene and (v) 609 C→T of the NQO1 gene. Results. The distribution of the genotypes of all tested polymorphisms was not different in patients and controls. No differences were seen among the patients when the group was subdivided by age and severity of the disease. Only the GSTM1 null genotype was significantly more frequent in male patients than in male controls. The frequency of all tested polymorphisms did not differ in patients who did or did not respond to immunosuppressive therapy. Interpretations and Conclusions. The low/null activity polymorphisms of the detoxifying enzymes CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 are not associated with the risk of developing aplastic anemia or to the response to immunosuppressive therapy in Caucasian patients.

KW - Aplastic anemia

KW - CYP3A4

KW - GSTs

KW - NQO1

UR - http://www.scopus.com/inward/record.url?scp=24944547455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944547455&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 1027

EP - 1031

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -